Lyell Immunopharma stock hits 52-week low at $0.51

Lyell Immunopharma Inc. (LYEL) stock has reached a new 52-week low, trading at $0.51, marking an 84% decline from its 52-week high of $3.15. According to InvestingPro analysis, the company currently appears undervalued based on its Fair Value assessment. This latest price point marks a significant downturn for the biotechnology company, which specializes in cancer immunotherapies. Over the past year, Lyell Immunopharma has seen its stock value decrease sharply, with a 1-year change showing a decline of -75.14%. While the company maintains a strong liquidity position with a current ratio of 7.06 and more cash than debt on its balance sheet, InvestingPro data reveals concerning trends, including rapid cash burn and analysts’ expectations of sales decline in the current year. This substantial drop reflects investor concerns and market reactions to the company’s performance and prospects within the competitive biotech industry. (Get access to 11 more exclusive InvestingPro Tips for LYEL and comprehensive financial analysis at InvestingPro).

In other recent news, Lyell Immunopharma has been notified by Nasdaq regarding non-compliance with the minimum bid price requirement, as its stock closed below $1.00 for 33 consecutive business days. The company has until July 22, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. If Lyell Immunopharma fails to meet this requirement, it may seek an additional 180-day extension by transferring to The Nasdaq Capital Market, provided it meets other listing standards. The company is exploring options such as a reverse stock split to address the issue. Meanwhile, H.C. Wainwright has reiterated a Neutral rating on Lyell Immunopharma, maintaining a price target of $1.00. The firm is closely monitoring the development of Lyell’s IMPT-314, a CAR-T candidate for treating large B-cell lymphoma. Analysts are particularly interested in upcoming data from the second-line setting of IMPT-314, which they plan to compare with existing standard-of-care therapies. Investors are paying close attention to these developments as Lyell Immunopharma navigates both clinical advancements and compliance challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.